NIAGARA: Perioperative durvalumab improves ctDNA clearance and clinical outcomes in patients with MIBC

EHA 2025

Lymphoma

ECHO: Frontline acalabrutinib triplet regimen improves clinical outcomes in patients with high-risk MCL

CHICAGO 2025

Genitourinary Cancer

Earlier initiation of ¹⁷⁷Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting

Further Publications

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703

J Clin Oncol

Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ

doi: 10.1200/JCO.24.00921

Multiple Myeloma (MM)

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

Eur J Cancer

Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B

doi: 10.1016/j.ejca.2024.115157

EHA 2024

Leukemia

Insights into clinical outcomes of patients with R/R AML after treatment with gilteritinib

Gastrointestinal Cancer

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

J Clin Oncol

Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK

doi: 10.1200/JCO.23.01462

WCLC 2024

Lung, Respiratory and Thoracic Cancer

TROPION-Lung01: Quantitative Continuous Scoring of TROP2 Normalized Membrane Ratio Predicts Clinical Outcomes in Patients With NSCLC

ASH 2024

Lymphoma

Improved management of CRS and ICANS in patients with R/R LBCL treated with axi-cel in clinical practice

Gastrointestinal Cancer

Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes